Fox Chase Cancer Center
333 Cottman Avenue
103 articles about Fox Chase Cancer Center
Beatrice Mintz, the research legend passed away at the age of 100. Her contribution to the field is unforgettable. ere's more about her and the research.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platform to improve drug discovery & development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with Fox Chase Cancer
Genome Profiling, Fox Chase Cancer Center to Collaborate on Immune System Blood Test to Predict Checkpoint Inhibitor Response in Non-Small Cell Lung Cancer
Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody.
MORE Health Announces Partnership with Fox Chase Cancer Center to offer Patients Remote Second Opinions
Fox Chase Cancer Center and MORE Health, a global healthcare company, announced a cutting-edge partnership that gives patients from across the world access to the nationally ranked physicians of Fox Chase Cancer Center through MORE Health's Physician Collaboration Platform™.
Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study
Natera, Inc. has partnered with Fox Chase Cancer Center to assess the company's Signatera™ customized circulating tumor DNA assay for recurrence monitoring of kidney cancer.
Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors
Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology.
Fox Chase Cancer Center Researchers Seek Breast Cancer Biomarkers That Indicate Immunotherapy Responsiveness
A small, but significant proportion of patients with invasive breast cancer have at least one of three biomarkers linked to ICB therapy, suggesting a role for such treatment for certain breast cancers, a new study shows.
GlaxoSmithKline’s Jerry Adams Joins Fox Chase Cancer Center As Visiting Professor
ReproCELL And Fox Chase Cancer Center Partner To Open Multi-Site Biosample Repository In India
Oncoceutics Release: Fox Chase Cancer Center Enrolling Patients In ONC201 Multiple Myeloma Trial
ReproCELL And Fox Chase Cancer Center Form Strategic Alliance To Accelerate Biomarker And Genetic Discovery
ERYtech Pharma Collaborates With Fox Chase Cancer Center To Advance Its Platform In The Field Of Rare Metabolic Disorders
Fox Chase Cancer Center Study: Pancreatic And Kidney Cancers Contain Noncancerous Niches That May Be Manipulated To Hinder Tumor Growth
Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies
Fox Chase Cancer Center Researchers Use New Methodology To Identify Neighborhood Variables Associated With Prostate Cancer Aggressiveness
Review By Fox Chase Cancer Center -- Temple Health And Temple University School Of Medicine Physicians Highlights Advances In Diagnosis And Treatment Of Bile Ducts Cancers
Caris Life Sciences And Fox Chase Cancer Center - Temple Health Collaborate On Potential New Treatments For Triple-Negative Breast Cancer (TNBC)
Oncoceutics Release: Clinical Trial For ONC201 Begins At Fox Chase Cancer Center